Analyst consensus rating
Neuropace Analyst Rating: Strong Buy
NPCE is rated Strong Buy by 9 analysts with a $20.22 target. As of 2026-08-22.
Direct answer
Neuropace's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.22.
Forecast evidence checked August 22, 2026.
Get free Neuropace email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $14.03
- Average price target
- $20.22
- High price target
- $22.00
- Low price target
- $18.00
- Low target gap
- +28.3%
- Target upside
- +44.1%
- High target gap
- +56.8%
- Target range width
- 28.5%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- August 22, 2026
- Valid through
- August 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Neuropace?
Neuropace has a verified Strong Buy consensus. The same dataset has an average price target of $20.22.
How far are Neuropace's low and high targets from the recorded price?
The low target implies +28.3%, while the high target implies +56.8%.
How many analysts are included in Neuropace's consensus?
The verified consensus includes 9 analysts.
How is Neuropace's target upside or downside calculated?
The average target of $20.22 is divided by the recorded price of $14.03, then one is subtracted to produce +44.1%. This does not guarantee a future return.
When was Neuropace's analyst forecast verified?
The data was verified on 2026-08-22. The dataset is valid through 2026-08-29.